1. Home
  2. IVVD vs DRUG Comparison

IVVD vs DRUG Comparison

Compare IVVD & DRUG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Invivyd Inc.

IVVD

Invivyd Inc.

N/A

Current Price

$0.46

Market Cap

212.6M

Sector

Health Care

ML Signal

N/A

Logo Bright Minds Biosciences Inc.

DRUG

Bright Minds Biosciences Inc.

N/A

Current Price

$20.61

Market Cap

228.0M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
IVVD
DRUG
Founded
2020
2019
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Pharmaceuticals and Biotechnology
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
212.6M
228.0M
IPO Year
2021
2020

Fundamental Metrics

Financial Performance
Metric
IVVD
DRUG
Price
$0.46
$20.61
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
9
Target Price
$10.00
★ $107.47
AVG Volume (30 Days)
★ 3.4M
261.1K
Earning Date
11-16-2026
08-17-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 79.02
N/A
EPS
N/A
★ N/A
Revenue
★ $53,426,000.00
N/A
Revenue This Year
$12.92
N/A
Revenue Next Year
$44.18
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
★ 110.47
N/A
52 Week Low
$0.49
$17.40
52 Week High
$3.01
$123.75

Technical Indicators

Market Signals
Indicator
IVVD
DRUG
Relative Strength Index (RSI) 30.94 26.79
Support Level N/A $17.40
Resistance Level $0.66 $58.93
Average True Range (ATR) 0.05 3.31
MACD -0.01 -0.07
Stochastic Oscillator 5.08 25.20

Price Performance

Historical Comparison
IVVD
DRUG

About IVVD Invivyd Inc.

Invivyd Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of monoclonal antibody (mAb) therapies for the prevention and treatment of serious viral infectious diseases. Its lead product, PEMGARDA (pemivibart), received emergency use authorization from the U.S. FDA for the pre-exposure prevention of COVID-19 in certain immunocompromised individuals. The company is also developing next-generation antibody candidates, including VYD2311 for COVID-19 and VBY329 for RSV infections, while continuing research on additional antibodies targeting other viral diseases such as measles.

About DRUG Bright Minds Biosciences Inc.

Bright Minds Biosciences Inc is focused on developing novel, transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult-to-treat disorders such as resistant epilepsy, treatment-resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.

Share on Social Networks: